The kidney health alliance between Vifor Pharma and ChemoCentryx Inc. is expanding to include the development and commercialization of CCX140 which is an orally administered inhibitor of CCR2, a chemokine receptor.
CCX140 has successfully completed a Phase II clinical trial for people with diabetic kidney disease.
The joint development of CCX140 in rare kidney diseases will be the main focus of the alliance. Vifor Pharma will retain an option to solely develop and commercialize CCX140 in prevalent forms of chronic kidney disease. ChemoCentryx will retain marketing rights for rare renal disease in the U.S. and China, with Vifor Pharma having commericialization rights in other countries.
“Expanding our kidney health alliance with Vifor Pharma to include CCX140 is an important step in our vision to establish ChemoCentryx as a leader in new medicines for rare renal diseases,” ChemoCentryx President and CEO Thomas Schall said. “We and Vifor Pharma believe that CCX140 has the potential to address life threatening renal diseases for which there are currently very limited treatment options. Building upon the extremely productive relationship with our partner so far, we very much look forward to expanding that relationship with this unique clinical asset.”
ChemoCentryx will be responsible for all clinical development of CCX140 in rare renal diseases and receive an upfront cash payment of $50 million.
